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Abstract
In patients with cerebral malaria (CM), higher levels of cell-specific microparticles (MP) correlate with the presence of
neurological symptoms. MP are submicron plasma membrane-derived vesicles that express antigens of their cell of origin
and phosphatidylserine (PS) on their surface, facilitating their role in coagulation, inflammation and cell adhesion. In this
study, the in vivo production, fate and pathogenicity of cell-specific MP during Plasmodium berghei infection of mice were
evaluated. Using annexin V, a PS ligand, and flow cytometry, analysis of platelet-free plasma from infected mice with
cerebral involvement showed a peak of MP levels at the time of the neurological onset. Phenotypic analyses showed that
MP from infected mice were predominantly of platelet, endothelial and erythrocytic origins. To determine the in vivo fate of
MP, we adoptively transferred fluorescently labelled MP from mice with CM into healthy or infected recipient mice. MP were
quickly cleared following intravenous injection, but microscopic examination revealed arrested MP lining the endothelium
of brain vessels of infected, but not healthy, recipient mice. To determine the pathogenicity of MP, we transferred MP from
activated endothelial cells into healthy recipient mice and this induced CM-like brain and lung pathology. This study
supports a pathogenic role for MP in the aggravation of the neurological lesion and suggests a causal relationship between
MP and the development of CM.
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Introduction
Cell activation by various agonists and apoptosis trigger the
vesiculation of microparticles (MP) from all cell types [1,2,3].
During vesiculation, phospholipids are reorganised through the
translocation of inward and outward membrane lipids, whereby
phosphatidylserine (PS) is exposed on the outer leaflet of the
membrane [4,5]. The budding progeny are small (0.2–1 mm)
plasma membrane-derived vesicles that express antigens of their
cell of origin and PS on their surface, facilitating their role in
coagulation, inflammation and cell adhesion [6,7].
Once described as inert biological bystanders MP have now
emerged as novel therapeutic targets in the treatment of diseases
[8,9,10]. Under normal physiological conditions, baseline levels of
circulating MP can be detected in the blood and are thought to be
involved in maintaining cellular homeostasis. However, elevated
levels of MP have been implicated in several diseases
[11,12,13,14,15,16,17,18], including cerebral malaria (CM), in
patients as well as in experimental models [19,20,21,22,23,
24,25,26].
CM is a multisystem multi-organ dysfunction that develops as a
syndrome following Plasmodium falciparum infection [27]. It is
characterised by the presence of sustained impaired consciousness
and those surviving may develop residual neurological sequelae
[28]. Despite better campaigns targeted at the eradication of
malaria, the global burden persists [29,30]. The underlying
pathogenesis that drives the manifestation of CM remains
incompletely understood. What is known is that the pathogenesis
is multifactorial, involving the dynamic interaction between
cellular sequestration, a dysregulated inflammatory response, MP
production and homeostasis disruption [24,31,32].
Little is understood about the role of MP in CM pathogenesis,
although markedly high plasma levels of circulating platelet,
erythrocytic, leucocytic and in particular endothelial cell-derived
MP (PMP, EryMP, LMP, EMP respectively) have been detected in
patients with CM [23,26,33]. In murine experimental CM (eCM),
the overproduction of MP is also observed, and ablation of MP
vesiculation via knock-down of the ATP-binding cassette trans-
porter A1 (ABCA1) involved in the distribution of PS, confers
protection against the neurological syndrome without interfering
with the infection itself [21]. Pharmacological inhibition of MP
production by pantethine also confers protection from CM [8].
The above findings indicate that MP may have an active role in
the development of the CM lesion and are not merely an
epiphenomenon, although the precise mechanisms of action of
these MP during CM have not been completely deciphered [20].
Using murine experimental models of CM [34,35] and non-
cerebral malaria (NCM) [36,37] we characterised the production
of MP over the course of Plasmodium infection in CM-susceptible
mice, and compared their cellular origins. We adoptively
transferred MP, isolated from mouse blood obtained at the time
of the neurological syndrome, into the circulation of recipient mice
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and followed their blood clearance. Our study dissects in which
tissues these MP localise to possibly exert their effects, as little is
known about their fate following their initial release. Since the
endothelium is an active component of the CM lesion, and EMP
have been found to be elevated in human CM (hCM) [23,38], we
transferred in vitro generated EMP and studied their induction of
pathology and clearance kinetics in healthy and infected mice.
This study shows MP localised at the neurovascular lesion in vivo
and MP transfer elicited CM-like histopathology in the brain and
lung of healthy recipients, supporting a role for MP in CM
pathogenesis.
Results
Kinetic production and characterisation of MP in CM and
NCM
Elevated levels of total circulating plasma MP detected in
CM+ mice. In our study, PbK infection at the non-encephali-
togenic dose (PbK) was used to model NCM, PbK infection at the
encephalitogenic dose (PbK1/2) and PbA infection (PbA) to model
CM (Figure 1). In our models, 100% of mice inoculated with PbA
and 70% of mice inoculated at the encephalitogenic dose with
16106 PbK developed CM within the neurological phase. Mice
infected at the non-encephalitogenic dose (26106 PRBC) of PbK
developed NCM and no cerebral complications. No significant
differences in the evolution of parasitaemia were observed between
the 3 infections on day 7 p.i (PbK, PbK1/2 and PbA, Fig. 1A).
Parasitaemia values for PbK and PbK1/2 after day 7 p.i diverge.
We collected PFP following P. berghei injection and quantified
circulating Annexin V+ MP over the course of infection. MP were
gated for their size and further analysed for Annexin V positive
populations using flow cytometry (Fig. 2A). In healthy mice, low
baseline levels of MP were detected (mean 6 SEM MP/mL,
27.662.3) and P. berghei infection triggered a rise in plasma
Annexin V+ MP levels (Fig. 2B). In PbA infected mice, numbers of
Annexin V+ MP peaked on day 2 (90.3620.3) and during the
neurological phase (60.366.2). High levels of Annexin V+ MP
were detected in the plasma of PbK1/2 infected mice on days 6 and
7 p.i, although this profile was different to PbA infection, notably
the absence of the peak at day 2 and the presence of the peak at
day 18 for the mice which did not develop CM. Mice infected with
PbK had a rise in MP levels on days 6 p.i. and on day 14 and 18
p.i (33.262.9; 39.2611.5; 1627.86251.7).
Plasma MP numbers were compared at the time of CM onset
(day 6–8) between the groups of infected mice, i.e. PbK-, PbK1/2-
and PbA (Fig. 2C). Annexin V+ MP were significantly increased in
mice showing signs of CM (PbA infected 60.366.2; PbK1/2
infected 53.463.6), when compared to healthy controls (27.662.3)
and infected mice not showing cerebral involvement (PbK infected
mean, 34.462.4; PbK1/2 infected mice with NCM are not shown
in figure). Interestingly, infected mice that develop CM displayed
higher levels of plasma MP than those that did not.
Elevated endothelial, platelet and erythrocytic MP at time
of CM onset. To evaluate whether Plasmodium infection could
directly or indirectly modify the cellular origin of MP present in
the plasma, we studied cell-specific MP level over the course of
infection by performing double staining for each cell marker
(Fig. 3) and PS. Although not significant, there was a trend for
CD105+ EMP to be elevated in the PbA infected group between
day 2 to 6, at day 14p.i. in the PbK infected group and remained
unchanged in the PbK1/2 infected group. High levels of CD41+
PMP were seen on day 2 p.i in the PbA infected group
(141.4657.9) and on day 14 in the PbK1/2 infected group
(NCM) (42.869.2). On day 7 p.i, TER119+ EryMP were elevated
in PbA infected mice (80.3633.8) compared to healthy (7.162.4)
and PbK infected mice (22.363). During the late stage of
infection, day 18, PbK infected mice exhibited higher levels of
TER119+ EryMP (170.9693.0), CD11b+ MMP (330.46117.7)
and CD45+ LMP (609.36205.1).
We studied the levels of cell-specific MP in the plasma at the
time of CM onset (Fig. 4A; PbK1/2 infected mice with NCM are
not shown in the figure). We found that EryMP (41.6612.3), EMP
(41613.3) and PMP (30.968.3) were most numerous in PbA
infected mice at the time of CM onset (Fig. 4A). In the PbA
groups, the levels of EMP, PMP and EryMP increased from
15.364.4, 10.062.4 and 7.162.4, respectively in the controls, to
41613.3, 30.968.3 and 41.6612.3 at the onset of CM,
respectively (Fig. 4B–D). In PbK1/2 infected mice, the levels of
PMP and EryMP increased at time of onset (32.565.5; 17.262.5)
with a decrease observed in EMP (0.960.2). No statistical
difference was observed with cell-specific MP between healthy
controls and PbK infected mice.
In vivo transfer and detection of MP
Rapid clearance of transferred MP in the circulation
following adoptive transfer. Fluorescently labeled MP, puri-
fied from the plasma of healthy and PbA infected donor mice,
were adoptively transferred into healthy or PbA infected recipient
mice. The presence of these MP was assessed in the blood of
recipient mice via flow cytometry over 60 minutes post injection.
MP from healthy donors were detectable in significantly lower
numbers than those from PbA infected donors. Injecting MP from
PbA infected donors induced an acute rise of MP in recipient mice
(mean 6 SEM MP/mL, 1018.56733.49 healthy recipient,
808.236329.75 PbA recipient) that cleared within 2 minutes
following injection (Fig. 5A).
MP from PbA infected donors localised in cerebral
microvessels of PbA infected recipients. Brain smears were
prepared from all recipient mice. Fluorescence microscopic
analysis showed that, after transfer, only MP from PbA infected
mice showing signs of CM (CM+) were found within the vessels of
the brain of CM+ recipient mice, but this was not evident in NCM
Author Summary
Cerebral malaria (CM) is a potentially fatal neurological
syndrome characterised by unrousable coma. Since the
detection of high levels of plasma microparticles (MP) in
patients with CM, it has been demonstrated that inhibition
of MP production confers protection from murine CM.
However, the precise mechanisms of action of these MP
during CM have not been completely deciphered. In this
study, we used experimental models of CM to measure the
production and origins of MP over the course of infection.
We found low baseline circulating MP in healthy mice and
these were subsequently raised at the time of the
neurological syndrome. Phenotypic analyses showed that
circulating MP were predominantly from activated host
cells that have previously been established to participate
in CM pathogenesis. We show for the first time transferred
MP impairing endothelial integrity and inducing CM-like
pathology in the brain and lung of healthy animals. Our
study dissects what tissues these MP localise to exert their
effects, as little is known about their fate following the
initial release. These data suggest a causal relationship
between MP and the development of CM and also warrant
further investigation into the representation of MP as a
marker of CM risk.
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Figure 1. Parasitaemia and survival curves of Plasmodium berghei. PbK-infection at the non-encephalitogenic dose was used to model NCM
(closed triangle), PbK-infection at the encephalitogenic dose (PbK1/2, open triangle) and PbA-infection to model CM (closed square) (n = 10). (A)
Parasitaemia and (B) survival curves during the course of the infections. No difference in percentage parasitaemia on day 7 p.i by the Mann Whitney
test: PbK (closed triangle) vs PbK1/2 (open triangle) p = 0.6286; PbK1/2 (open triangle) vs PbA (closed square) p = 1; PbK (closed triangle) vs PbA (closed
square) p = 0.5333. Note, parasitaemia values for PbA infected mice after day 7 are not shown, since none were surviving. Parasitaemia values for PbK
and PbK1/2 after day 7 p.i diverge. Parasitaemia is shown as mean 6 SD. CBA mice (n = 10, per group) infected with PbK1/2 or PbA parasites develop
CM, with a cumulative incidence of 70% and 100% respectively. Comparison of survival curves PbK (closed triangle) vs PbK1/2 (open triangle): Log-
rank (Mantel-Cox) Test p,0.001 and Gehan-Breslow-Wilcoxon Test p,0.002. PbK1/2 (open triangle) vs PbA (closed square): Log-rank (Mantel-Cox)
Test p,0.001 and Gehan-Breslow-Wilcoxon Test p,0.001. PbK (closed triangle) vs PbA1/2 (closed square): Log-rank (Mantel-Cox) Test p,0.001 and
Gehan-Breslow-Wilcoxon Test p,0.001.
doi:10.1371/journal.ppat.1003839.g001
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mice. MP were found to be lodged along the endothelium within
the lumen and at the bifurcation of some but not all microvessels.
When the recipient mice were healthy, no MP could be visualised
within the cerebral microvessels (Fig. 5B, Table 1). Similarly,
transferred MP from healthy donors were absent in the vessels of
both healthy and CM+ recipient mice (Fig. 5B, Table 1).
Transferred MP are trapped in both PbA infected and
healthy recipient spleen. To determine the major route of
clearance for the adoptively transferred MP we imaged the spleen,
kidney, liver, lung and heart of recipient mice. Observations made
on all combinations MP-donor/MP-recipient and the presence of
MP within these organs are represented in Table 1 (and in Fig.
S1).
MP from both healthy and PbA infected donors were present in
the red pulp of the spleen of all recipient mice (Table 1). CM+ MP
were distributed in CM+ kidney and to a lesser extent in CM+ lung
and CM+ liver. No MP were present in the heart, an organ
without any known CM pathology (Table 1).
Transferred EMP induced several histopathological
anomalies in the brain and lungs of recipient mice. EMP
purified from resting or TNF-stimulated MVECs in vitro were
labelled and transferred into healthy or PbA infected mice to
investigate their role in the CM lesion. EMP could be detected
circulating in the first few minutes post-transfer compared to the
control microsphere beads that continued to circulate longer
(Fig. 6A) and could be detected for up to 60 minutes (Fig. 6A, data
shown only until 30 min).
To identify possible markers that could be facilitating the
interaction of EMP at the site of the lesion, the surface phenotype
of EMP was determined. We found that CD54 and CD106
(Fig. 6B) were present on EMP from resting cells and the numbers
of CD54+ and CD106+ EMP in the supernatant increased
Figure 2. Total plasma microparticle levels during Plasmodium berghei infection. (A) Cytogram representation of total Annexin V+ MP per
mL of plasma in infected CBA mice. MP were gated for their size and further analysed for positive Annexin V+ populations. Calibrated fluorescent latex
beads of a known size and concentration were used as an internal standard to calculate MP levels. (B) Increase in total Annexin V+ MP following
Plasmodium berghei infection. Mice infected with 16106 PbA (closed square) display a biphasic production of MP, peaking at day 2 and day 7, which is
not observed in mice infected with PbK (closed triangle) or PbK1/2 (open triangle). MP levels are plotted in MP/mL of plasma; 1-way ANOVA, Kruskall-
Wallis & Dunns post-test *p,0.05, **p,0.001, ***p,0.0001. Annexin V+ labelling was performed on 5 PFP samples from each mouse. Data shown
from n= 10 PbK (closed triangle) and n= 5 PbK1/2 infected (open triangle) mice on day 0, 2, 4, 6, 7, 14 and 18. Data shown from PbA infected mice
(closed square) n = 11 day 0, n = 10 day 2, n = 10 day 4, n = 12 day 6, n = 6 day 7, n = 5 day 8. (C) Annexin V+ MP per mL of plasma at time of CM onset.
CM+ mice (i.e. Infected with PbK1/2 (dark grey) or PbA (black)) have higher levels of circulating MP than CM2 mice (i.e. non-infected (white) and PbK
infected mice (light grey)). Data from PbK1/2 infected mice that did not display signs of CM are not shown. Mann Whitney t-test *p,0.05, **p,0.001,
***p,0.0001.
doi:10.1371/journal.ppat.1003839.g002
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following TNF-stimulation (mean 6 SEM MP/mL; CD54:
9.85061.064 to 38.05069.925; CD106: 86.18369.981 to
133.250619.860). To characterise the extent of pathology induced
by the transfer of EMP, we examined multiple haematoxylin-eosin
stained representative brain and lung sections from each group
sampled on day 7 post-infection (Fig. 6C–D) and scored the 3
main pathological features of CM, i.e., sequestration, enlarged
perivascular spaces (PVS) and haemorrhages. Enlarged PVS were
present in brain sections of healthy mice injected with NS-EMP or
TNF-EMP and not in sections sampled from mice treated with
PBS or beads (p , 0.05). Evidence for vessel disruption and
haemorrhages were seen in brain sections from uninfected mice
injected with TNF-EMP. These histological changes closely
resembled brain sections of PbA infected mice treated with PBS
and control beads. In the EMP-injected uninfected lung, we found
signs of pulmonary inflammation including hyperplasia of alveolar
epithelium and the presence of increased numbers of leucocytes in
alveolar septa (Fig. 6C). Both NS-EMP and TNF-EMP induced
thickening of the alveolar septa, atelectasis and haemorrhages,
closely resembling the ARDS-like pathology usually seen in PbA
infected mice. Injection of beads or PBS did not appear to alter
lung histology.
Discussion
This study investigates the levels and cellular origin of MP
produced during murine malaria and for the first time describes
the clearance and fate of CM+ MP in vivo as well as the
pathogenicity of EMP. Using CM-susceptible mice, we showed
that P. berghei infection induces a rise in total circulating MP,
although distinct differences exist in the cellular origin and
production profiles of MP in mice developing CM versus NCM.
We found that MP from CM+, but not healthy donors, adoptively
transferred in vivo can be detected at the site of the lesion,
sequestered amongst other cells within the cerebral vessels of CM+
recipient mice. We also showed that transferred EMP,induce CM-
like pathology in the brain and lung of recipient mice, supporting a
role for MP in the exacerbation of CM.
Ablating the increase of MP numbers either genetically [21] or
pharmacologically [8] confers protection against murine CM.
Elevated levels of plasma EryMP [33] and EMP [23,38] in malaria
patients correlate with severity and are particularly restricted to
those with cerebral involvement. This also has been shown in
studies on intracerebral haemorrhage, whereby higher MP levels
correlate with coma and poor clinical outcome in patients
[39][40]. Although suggestive of a role in the pathogenesis of
CM, the existing data on MP in CM does not completely support
a role for MP in the worsening of CM nor do they substantiate it
solely as a predictive marker for CM.
Elevated levels of circulating Annexin V+ MP were detected in
the plasma of CM+ mice (i.e. infected with PbA or PbK1/2) at the
time of neurological development. This finding confirms what has
already been observed upon CM onset in experimental and hCM
[21,38]. Our study extends from this and follows the production of
MP over the course of infection, not just at CM onset.
Interestingly, a biphasic production of MP was detected in the
Figure 3. Cell-specific MP in plasma during the course of
Plasmodium berghei infection of CBA mice. PbK (closed triangle),
PbK1/2 (open triangle) or PbA (closed square) (A) PMP/mL plasma; (B)
EMP/mL plasma; (C) RMP/mL plasma; (D) MMP/mL plasma; (E) LMP/mL
plasma. Data shown from n= 10 PbK- (closed triangle) and n= 5 PbK1/2
infected (open triangle) mice on day 0, 2, 4, 6, 7, 14 and 18. Data shown
from PbA infected mice (closed square) n= 11 day 0, n= 10 day 2, n= 10
day 4, n= 12 day 6, n= 6 day 7, n= 5 day 8 and represented as mean 6
SEM *p,0.05, **p,0.001, ***p,0.0001. Inconsistencies in sample
group size are due to the fragile health status of mice during the
period of morbidity.
doi:10.1371/journal.ppat.1003839.g003
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plasma of PbA infected mice, peaking during the early stages of
infection and also at CM onset. These waves of MP coincide with
the perpetuated cycle of endothelial activation, the production of
cytokines and chemokines, the upregulation of adhesion molecules
and the binding of vascular cells to microvessels [41]. Although the
first wave of MP was absent in PbK1/2 infection, mice with high
MP levels during the neurological phase did develop CM. MP
overproduction was absent in mice that did not develop cerebral
signs during the time of CM onset in PbA mice (i.e. PbK infected
or 30% of the PbK1/2 infected). This suggests that MP may play a
role in the development of the neurological syndrome.
At the time of CM onset, cell-specific MP numbers were higher
in PbA infected mice than in PbK- and PbK1/2 infected animals or
healthy controls. The sum of positive MP for single staining of cell
Figure 4. Cell-specific MP in plasma at CM onset in CBA mice. (A) Levels of total cell-specific MP in plasma at time of CM onset: platelet-MP
(PMP, white), endothelial-MP (EMP, light grey), erythrocytic-MP (EryMP, dark grey), monocytic-MP (MMP, black), leucocytic-MP (LMP, striped). (B–F)
Cell-specific MP levels per mL of plasma at time of CM onset: non-infected (white bar), PbK (light grey bar), PbK1/2 (dark grey bar), PbA (black bar). B.
PMP. C. EMP. D. RMP. E. MMP. F. LMP. Data shown from n= 25 healthy, n= 20 PbK infected and n= 10 PbK1/2 infected mice showing signs of CM on
day 6 and 7 p.i. and from n= 23 PbA infected mice collected on day 6, 7 and 8 p.i., and represented as mean 6 SEM. *p,0.05, **p,0.001, ***p,
0.0001.
doi:10.1371/journal.ppat.1003839.g004
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Figure 5. Detection, clearance, and tissue distribution of MP following adoptive transfer. (A) Clearance of transferred MP within
circulation following adoptive transfer. The presence of transferred PKH67-labeled MP was detected via flow cytometry in the blood of recipient mice.
MP were detectable immediately following intravenous injection; healthy recipients (circles) cleared the MP quicker than PbA infected recipients
Microparticles in Murine Cerebral Malaria
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markers gave a closer approximation of total circulating MP, as
Annexin V staining indicates only PS-positive MP. MP can be PS
negative or have low undetectable PS on the surface and remain
unbound to Annexin V [20,42]. We found that plasma PMP,
EMP, EryMP and MMP were most elevated during the
neurological phase in PbA infected mice. Previous studies have
shown a dramatic increase in EMP, EryMP and PMP in patients
presenting with CM [23,33,38]. In CM, the neurovascular lesion is
comprised of sequestered vascular cells such as platelets, erythro-
cytes and leucocytes within the endothelial lining of microvessels
[32,43,44]. It is not surprising that the sequestered cells also
produce the most predominant MP populations detected. The
development of CM is attributed to the cascade of events
preceding the sequestration of cells and, consequently, the
mechanical occlusion [31,43,44,45]. The 70% of PbK1/2 infected
mice that developed CM displayed comparable levels of total
Annexin V+ MP levels to PbA infected mice, although their origins
were predominately from platelets and erythrocytes. No significant
differences were detected between the levels or proportions of
cell-specific MP detected in PbK infected and healthy mice
between days 6 and 14.
Our data show that during the acute stage of PbA-infection, a
peak of PMP can be detected, and this is absent in the PbK- and
PbK1/2-infections. This finding is consistent with the substantial
loss of platelets as MP in the acute phase of the PbA-infection [46]
and may correlate with the depth and duration of coma [38].
Thrombocytopenia is associated with poor prognosis in both
human and experimental CM [46,47] and higher platelet
accumulation has been observed in cerebral microvessels in both
human [48] and eCM [49,50]. In vitro, platelets enhance the
binding of infected erythrocytes (IE) to the cerebral endothelium
[51] and their MP progeny are able to adhere preferentially to IE
and also to the cerebral endothelium [19,52]. PMP pathogenic
potential is attributed to their mobility and their access via blood
flow to other vascular cells [53]. Although this finding supports the
platelet adhesion hypothesis, the absence of this first wave of PMP
in PbK1/2 infection is interesting. Nothing is known about
thrombocytopenia or PMP in PbK1/2 infection. The majority of
(squares). Data are mean 6 SEM from n= 3 per group. (B) Microparticles localised in brain microvessels of CM+ recipient mice. Smears were prepared
from healthy and CM+ mice, recipients of PKH67-labelled MP (green) purified from healthy or CM+ donor mice (n= 3). MP were activated in vitro with
calcium ionophore (A23187), a known vesiculating agonist, labelled, intravenously transferred and allowed to circulate for 1 h. Brain smears were
fixed and counter-stained with Texas Red Lectin and DAPI to identify vessels (red) and nuclei (blue), respectively. MP from CM+ donors can only be
detected in the microvessels of CM+ recipient mice (arrows). Imaged on Olympus IX71. Insert: MP from CM+ donor lodged in CM+ brain vessel, imaged
using oil immersion660 on Olympus FluoView FV 1000 confocal microscope. Arrows indicate MP lining the endothelium amongst other cells and
trapped in birfurcation of vessels. (C) Summary of MP localisation in cerebral vessels. MP from CM+ donors can only be detected in the microvessels of
CM+ recipient mice, as indicated by green tick.
doi:10.1371/journal.ppat.1003839.g005
Table 1. Qualitative summary of PKH67-labelled MP distribution within the tissue of recipient mice following adoptive transfer.
Donor Recipient MP present
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Figure 6. Transferred EMP generated in vitro induce CM-like pathology in healthy mice. (A) Detection of PKH-67 labelled EMP in the blood
of recipient mice following transfer. Purified EMP (4006103/mouse) from TNF stimulated and resting mouse brain microvascular endothelial cell line
B3 harvested in vitro, were transferred into PbA infected and healthy recipient mice. Clearance of fluorescently labeled EMP from the blood was
monitored by flow cytometry. Latex beads (4006103/mouse, control) can be detected in constant circulation up to 30 minutes post transfer. Data
represent the mean from n= 3. Closed circle/solid line indicates beads transferred into healthy mice, open circle/interrupted line indicates beads
transferred into infected mice, closed square/solid line indicates NS- EMP transferred into healthy mice, closed triangle/solid line indicates NS-EMP
transferred into infected mice, open square/interrupted line indicates TNF-EMP transferred into healthy mice and open triangle/interrupted line
indicates TNF-EMP transferred into infected mice. (B) Detection of CD54 and CD106 on in vitro generated MP derived from mouse brain microvascular
endothelial cells. Graph shows the expression of CD54 (white bar) and CD106 (black bar) on resting and TNF-stimulated EMP. Data are mean 6 SD,
*p,0.05. The numbers of CD54+ and CD106+ EMP in the supernatant increased following TNF-stimulation (mean 6 SEM MP/mL; CD54: 9.85061.064
to 38.05069.925; 74.11% CD54+ shift CD106: 86.18369.981 to 133.250619.860; 35.32% CD106+ shift). (C) Representative haematoxylin-eosin brain
and lung sections from healthy and PbA infected mice treated with PBS or EMP (n= 3) on day 6 p.i. Morphometric analysis reveals that EMPs induce
significant pathology in healthy brain and lung. In the brain, the arrows heads indicate areas of engorged vessels and haemorrhage. In the lung,
multifocal lesions, abnormal cellularity in the alveolar septa, plasma in alveoli and haemorrhage. Treatment with EMP in healthy mice induces
haemorrhage in the brain (white arrow head) and increased cellularity (white arrow head) and atelectasis (white arrow) in the lung of recipient mice.
Such pathology is not observed in the mice treated with PBS or beads alone. Scale bar (bottom left) indicates 40 mm. (D) Effects of in vitro generated
Microparticles in Murine Cerebral Malaria
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mice develop CM+ despite the absence of the first wave of PMP;
nevertheless, at CM onset, higher titres of PMP are detected.
EryMP were elevated in CM+ mice, both in PbA- and PbK1/2
infected mice, at CM onset. This finding is supported by human
studies, whereby EryMP numbers are increased in patients with P.
falciparum infections, even after antimalarial drug treatment [33]
and also in patients with severe malarial anaemia [38]. In contrast,
EryMP numbers are lower in patients with P. vivax and P. malariae
malaria, similar to what is observed with the PbK infected mice in
our study [33]. Interestingly, the PbK infected group, with no
evidence of cerebral complications, had an overproduction of MP
from erythrocytes and leucocytes during the later stage of
infection. The evolving hyperparasitaemia in these mice leads to
the destruction of IE and the gradual rupture and fragmentation of
fragile erythrocytes increases the level of EryMP and cellular
debris [33]. Higher levels of LMP could account in that case for
the activation of the cells involved in the destruction of
erythrocytes and their removal from the circulation.
Adoptively transferred CM+ MP are detectable in recipient
mice but quickly subsided, indicating clearance from circulation.
Some of these MP were found to be arrested in cerebral
microvessels of CM+ recipients and also in the spleen, kidney
and, to a lesser extent, the lung and liver. Recent studies in
humans have shown that parasites induce the loss of endothelial
protein C receptors in the cerebral microvessels, leaving them
vulnerable to enhanced local thrombin generation and coagulop-
athy [54]. We know from previous murine studies that MP are
procoagulant and proinflammatory [21,43,55], thus it is not
surprising that MP are found lodged in the cerebral microvessels of
infected recipients. No MP were detected in the heart of recipients.
MP from both healthy and CM+ donors were also detected within
the spleen of recipient hosts, suggesting that this organ could be a
site of MP trapping and clearance from the circulation indepen-
dent of the infection. It is possible that the spleen filters the PS+
MP in a similar way to PS+ cells in malaria [56] and Kupffer cells
in the liver could remove EryMP as shown by Willenkens et al.,
[57], although further studies are required to elucidate this in our
system.
Little is known on the mechanisms underlying the clearance of
plasma MP from circulation in vivo. In our study, the disappear-
ance of PKH67-labelled CM+ MP occurred within 5 minutes. In a
rabbit model, no PMP were detected in the circulation at 10, 30 or
60 minutes post injection [58]. In contrast, transferred PMP,
isolated from platelet concentrates from the peripheral blood of
single donor patients, circulated for markedly longer with a half-
life of 5.8 hours (Annexin V+) and 5.3 hours (CD61+) [59]. The
authors attribute the elevated levels and the longer half-life of
circulating MP to the infused platelets producing more MP in
circulation [59]. Another possible explanation is that MP may
clear the circulation and reach their target sites quicker in rabbit
models, and also in mice, due to their faster heart rate [58]. The
authors also suggest that the half-life is an overestimation, and the
observations in the rabbits miss the initial rapid clearance of MP
[58]. Furthermore, in vitro assays support the idea that MP can be
detected in blood when there is no mechanism to remove them
[58]. In pathological states, the continuous production of MP
overrides the mechanisms of rapid clearance, hence elevated levels
can be detected.
All cells are able to produce and release MP, although the
emerging progeny of MP are heterogeneous and do not share the
same properties. EMP represent the most abundant MP detected
in pathologies that arise due to vascular injury or endothelial
dysfunction although not all their roles are noxious [60,61]. EMP
numbers are elevated in patients with conditions in which the
endothelium is injured and/or the endothelial barrier is compro-
mised, including sickle cell disease, Alzheimer’s disease, metabolic
syndrome, hypertension, atherosclerosis and chronic obstructive
pulmonary disease [62,63,64,65,66,67]. EMP were first described
in vitro [6] and high numbers were detected in CM patients
presenting with coma [23]. Lower numbers of EMP and
concentrations of TNF were detected in mice protected against
CM during PbA infection [21]. Studies in vitro and in the murine
model of CM indicated that EMP have similar procoagulant and
pro-inflammatory potentials to, and express the same repertoire of
antigens as, their corresponding mother EC [6,21]. In CM, the
endothelium is both a target and an effector in disease
pathogenesis [24]. The direct role of EMP in inducing brain
and lung pathology in murine models of CM has not been
described. We addressed the hypothesis that EMP may be
pathogenic in the CM lesion by transferring TNF-generated
EMP into healthy and infected mice. Our findings demonstrate
that transferred TNF-EMP can induce histopathological signs that
are compatible with endothelial leakage leading to cerebral and
pulmonary oedema and haemorrhage in healthy mice [68].
Control inert microsphere beads did not induce any change and
remained in circulation for 60 minutes, compared to EMP that
were cleared within the first few minutes post transfer, supporting
the idea that the clearance of the MP is a physiological
phenomenon that is mediated by receptors present at the surface
of MP.
Exactly how EMP alter endothelial integrity in CM is unclear.
Flow cytometry revealed that our EMP express endoglin, CD54
and CD106. Soluble endoglin (sCD105) overexpression is linked to
typical systemic and vascular inflammation states such as pre-
eclampsia and HELLP syndrome [69]. It is possible that endoglin-
bound MP may have a role in inducing vascular injury. Endoglin
is an RGD membrane protein acting as transforming growth
factor-b accessory receptor and has been implicated in leucocyte
recruitment and extravasation [70] and more recently in septic
shock-induced disseminated intravascular coagulopathy [71]. In
CM, CD54 and CD106 are established markers of EC injury and
enable tethering and sequestration of cells to the endothelium
[31,43,72]. TNF increased the expression of CD54 and CD106 on
the EMP, consistent with other studies [25], suggesting a possible
mechanism by which MP interact with the endothelium to induce
injury.
Transferred EMP induced atelectasis in lungs from healthy
recipient mice and increased alveolar cellularity, resembling the
pathology seen in CM+ lung. EMP were shown to induce
endothelial dysfunction, promote vasodilation, pulmonary oedema
and acute lung injury in pathophysiological concentrations [73].
EMP sequester in lung tissue and elicit an immune response in vivo
by increasing cytokine production leading to neutrophil recruit-
ment [73,74]. It is plausible that EMP initiate a cascade of events,
beginning with the production of cytokines, that prime the
endothelium thereby ultimately impairing vessel functions and
resulting in tissue damage.
Taken together, our findings offer new evidence for a causal
relationship between MP and the pathogenesis of CM. To our
knowledge, this is the first time that MP have been localised at the
EMP on healthy and PbA infected brain and lung in the following treated groups: PBS (white bar), beads (light grey), NS-EMP (dark grey) and TNF-EMP
(black). Representative Haematoxylin-Eosin images (n= 3) per group were scored for histopathological signs (Table 3).
doi:10.1371/journal.ppat.1003839.g006
Microparticles in Murine Cerebral Malaria
PLOS Pathogens | www.plospathogens.org 10 March 2014 | Volume 10 | Issue 3 | e1003839
neurovascular lesion in vivo and that their transfer elicited
histopathology in the brain and lung of healthy recipients. We
confirm that elevated levels of total MP are present at CM onset,
predominantly from activated host cells that are known to
participate in CM pathogenesis. Specifically, in CM, the early
peak of total MP and PMP differentiated the kinetic production
profile from NCM and could potentially be an indicator of
prognosis. We showed that MP are rapidly cleared from
circulation, and that some remain sequestered in organs, such as
the brain and spleen. The EMP in this study carry VCAM-1 and
ICAM-1 on their surface, which are upregulated following
cytokine stimulation, potentially mediating their role in the
worsening of CM.
During CM, activation of cells by parasite moieties, toxins,
cytokines and/or cell death, delivers MP into the circulation. We
propose that the interactions between MP, endothelium, circulat-
ing host vascular cells and their released circulating soluble factors
influence the course of infection leading to the development of
CM. Since the first human studies on MP in CM [23,38], there
has been growing interest in exploring the potential of MP as
biomarkers for both diagnosis and follow-up and therapeutic
targets since they represent both a consequence of, and
contributor to, CM. The plasma membrane acts as the primary
sensor to its external environment, thus, discriminating the cellular
origin of MP may indicate what tissues or cells are undergoing
activation or damage. Besides detection of malarial retinopathy,
which is yet to be included as standard assessment for severe
malaria, a clinical challenge still exists to distinguish CM from
other encephalopathies [75]. Diagnosis relies on P. falciparum
parasitaemia and impaired consciousness with the exclusion of
other potential causes of severe disease, which in malaria-endemic
areas is difficult to achieve due to the prevalence of asymptomatic
parasitaemia and the lack of high-level diagnostic testing.
Misdiagnosis is common and there is a need for reliable CM
specific diagnostic and prognostic biomarkers [76]. This would
support the promise of MP as clinical probes for CM and help
provide targeted care of malaria patients at imminent risk of organ
damage or cerebral complications as indicated by their detected
MP [11].
In addition, molecules such as Pantethine that inhibit MP
release have conferred protection in vivo and may be suitable
candidates for an adjunct neuroprotective treatment of CM [8]. If
the delay of CM onset in vivo is observed in human patients, this
could potentially increase the therapeutic window available for
treatment decreasing CM-associated mortality and neurological
sequelae. In combination with anti-parasite chemotherapy,
molecules that stabilize plasma membranes and reduce overpro-
duction of deleterious MP and shedding may be protective or
minimise the cerebral complications associated with CM.
Materials and Methods
Infections were performed as previously described [34][37][38].
All protocols adhered to the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes. All protocols
were approved by the Animal Ethics Committee of the University
of Sydney (K20/7- 2006/3/4434 and K00/10-2010/3/5317).
Detection and characterisation of plasma MP in mice
with CM and NCM
i. Mice and infection. Seven to 8 weeks old female CBA
mice (Animal Resource Centre, Perth) were housed under
pathogen-free conditions. These mice are susceptible to Plasmodium
berghei-ANKA (PbA) infection, and thus succumb to CM during
the neurological phase, between day 6 and 14 post-infection (p.i)
[37]. We induced CM in mice by intraperitoneal injection of
16106 PbA-parasitised red blood cells, as previously described
[32] and 16106 Plasmodium berghei-K173 (PbK). NCM in mice was
induced by infection with 26106 PbK-parasitised red blood cells
[34]. It is noteworthy that the PbA genome and pathogenicity are
close to Plasmodium falciparum, the causative agent of hCM, whereas
PbK results in different pathogenicity (resembling P. vivax).
Moreover, the early cytokine profile is different with increased
IFN-c production related to inoculum conferring protection
against CM being observed only during PbK infection [77].
Parasitaemia was determined from thin tail blood smears on day
4 p.i and every second day until end point, using light microscopy
and Diff-Quick staining. CM was diagnosed if an infected mouse
presented with ruffled fur, severe motor impairment (ataxia,
hemiplegia or paraplegia) or convulsions and was allocated a score
of 3 or 4 as described previously [38]. Each mouse was also
evaluated for the severity of CM using the clinical evaluation score
[38]. Diagnosis was then confirmed by histopathology. Infected
mice without any of the above mentioned symptoms were classed
as NCM.
ii. Blood sampling and processing forMP analysis. Mouse
venous blood was collected by retro-orbital venepuncture under
anaesthesia in 0.129 mol/L sodium citrate (ratio of blood to
anticoagulant 4:1). Samples were centrifuged at 1 500 g for 15 min
at room temperature. Harvested supernatant was further centri-
fuged at 18 000 g for 4 min, twice, to achieve platelet-free plasma
(PFP).
iii. MP characterisation. Total MP numbers were quanti-
fied by detection of PS using FITC-Annexin V (Beckman Coulter)
labelling, which is Ca2+ dependent. The cellular origin of these
MP was determined using cell-specific monoclonal antibodies as
detailed in Table 2.
Briefly, 20 ml of PFP were incubated with Annexin V-FITC
diluted 1 : 2 in 106binding buffer (BB) or antibodies for 30 min.
Following incubation, 20 mL of Flow-countTM Fluorospheres
(1000/mL) (Beckman Coulter) were added to each sample to act
as a calibrated internal standard of known size and concentration.
Samples were resuspended in 200 mL of 16BB and analysed on a
Beckman-Coulter FC500-MPL flow cytometer. Data were ac-
quired for 60 s and analysed using CXP analysis software
(Beckman Coulter). MP were first discriminated based on their
size (,1 mm) on a log-forward light scatter and log-side light
scatter (FSC-SSC) dot plot and then for their positivity for binding
of either Annexin V or specific antibodies (Fig. 2A). Due to their
large size (10 mm) and high fluorescence, flow count beads could
be discriminated from the MP population and gated accordingly.
Clearance and tissue distribution of MP following
adoptive transfer
i. MP purification and preparation. Blood was collected
by venepuncture of the retro-orbital plexus in sterile citrated tubes
from healthy and PbA infected mice displaying full blown
syndrome. In order to maximise the number of MP purified
without changing the phenotype of MP produced by the blood
cells and to minimise the number of donor mice, whole blood was
activated using calcium (Ca2+)-ionophore (Calcimycin A23187
2 mmol/L, SIGMA) vortexed and incubated at 37uC for 40 min.
Calcium ionophore activation of whole blood increases the
number of MP by two – three fold. Blood was processed for
PFP as mentioned above. To obtain a purified population of MP
devoid of blood proteins and calcium ionophore, PFP was further
centrifuged at 18 000 g for 1 h at 15uC. Supernatant was used as a
MP-free control after checking by flow cytometry. The MP pellet
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was gently resuspended in Diluent C (Sigma), prior to labelling
using PKH67 Green Fluorescent Cell Linker Kit for General Cell
Membrane Labelling (SIGMA). Briefly, under dark sterile
conditions 1 mL of PKH67 was added to 250 mL of Diluent C
and then added to 250 mL of MP suspension. Following
continuous pipetting for 1 min, the suspension was incubated in
the dark for 4 min. Labelling was stopped by adding 2 mL of
foetal bovine serum (FBS) and 10 mL of RMPI-1640 containing
10% FBS (Gibco). The suspension was centrifuged at 18 000 g for
1 h at 15uC to pellet MP. PKH67+MP were resuspended in PBS
and numbers were calculated after flow cytometry analysis.
ii. Adoptive transfer and detection of transferred MP in
circulation by flow cytometry. PKH67+MP suspensions and
MP-free supernatant were injected intravenously into healthy and
PbA infected recipient mice 6 days p.i. Briefly, mice were
anesthetised and received 4006103 MP in 200 mL of PBS. Mice
were allowed to recover. Blood was collected via tail vein at
selected time points (1, 2, 3, 4, 5, 10, 20, 30, 40, 50 and 60 min)
and analysed by flow cytometry prior to euthanasia and
subsequent collection of organs. Briefly, 5 mL of mixed blood
and citrate and 5 mL of Flow-count fluorospheres (Beckman
Coulter) were resuspended in 200 mL of PBS. MP present in the
samples were counted based on their size and PKH67 labelling.
iii. Tissue collection and immunofluorescence imag-
ing. Following euthanasia, brains were collected and cut along
the sagittal plane. By placing a small (1 mm61 mm) section of
fresh brain between two glass microscope slides and pressing these
together, brain smears were created. Smears were allowed to air
dry completely prior to fixation and subsequent labelling. The rest
of the brain, together with lung, spleen, liver, kidney and heart
tissue, were placed in cryoprotective embedding medium (OCT)
and snap frozen in hexane cooled with liquid nitrogen. Tissue was
then cut into 5 mm sections. Sections and brain smears were fixed
in precooled (30 min at 220uC) absolute ethanol and acetone (3 :
1) for 10 min. Following blocking with filtered 5% (w/v) bovine
serum albumin in PBS for 20 min, slides were incubated with
Texas Red labeled Lycopersicon Esculentum (Tomato) Lectin
(LEL, TL, Vector Laboratories) for 45 min at room temperature.
Slides were washed and stained with 49, 6-diamidino-2-pheny-
lindole (DAPI) fluorescent stain (Invitrogen) and mounted in
Fluoromount-G (Southern Biotech). Images were obtained using
an Olympus IX71 inverted microscope and also the confocal
microscope Olympus FV1000, as noted.
Passive transfer of in vitro generated EMP
i. Cell culture, EMP generation, characterisation and
transfer. EMP were generated from mouse brain microvascular
endothelial cells (B3 cell line) in vitro, isolated as described
previously [39]. Cells were maintained in RPMI 1640 (Gibco)
supplemented with 10% FBS at 37uC in a 5% humidified CO2
incubator. Cells were grown to subconfluence and were stimulated
with TNF (50 ng/mL) overnight (TNF-stimulated EMP, TNF-
EMP). The supernatant was collected from multiple flasks, pooled
and centrifuged to pellet MP, which were resuspended in PBS.
Briefly, cells in suspension and large debris were eliminated by
1 800 g centrifugation for 10 min, then the supernatant was twice
Table 2. Detection of cell-specific markers.
Cell-type Marker Alternate name Clone Supplier Concentration used
Endothelial cell CD105 Endoglin MJ7/18 eBioscience 5 mg/mL
Erythrocyte TER-119/CD235a Erythroid cell marker TER-119 eBioscience 2 mg/mL





Monocyte CD11b Integrin aM M1/70 eBioscience 2 mg/mL





CD54 ICAM-1 YN1/1.7.4 eBioscience 10 mg/mL
Vascular Cell Adhesion
Molecule-1
CD106 VCAM-1 429 eBioscience 10 mg/mL
doi:10.1371/journal.ppat.1003839.t002
Table 3. The qualitative histopathological scoring of the tissue.
Score
Tissue Parameter 0 1 2 3 4
Brain Sequestration None present * ** *** ****
PVS No changes * ** *** ****
Haemorrhage None present * ** *** ****
Lung Cellularity None present * ** *** ****
Atelectasis None present * ** *** ****
Plasma None present * ** *** ****
Haemorrhage None present * ** *** ****
doi:10.1371/journal.ppat.1003839.t003
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further centrifuged at 18 000 g to eliminate traces of the original
culture medium and the final pellet was resuspended in sterile
PBS. For controls, we used MP purified from supernatant
collected from resting cells (non-stimulated MP (NS-EMP)) and
Fluoresbrite Yellow Green Microspheres 0.75 mm (Polysciences,
Inc.) (beads). Samples of EMP were phenotyped by incubation
with anti-mouse monoclonal antibodies directed against CD54
(ICAM-1), CD105 (endoglin), CD106 (VCAM-1) and analysed by
flow cytometry. Before transfer, EMP were labelled with PKH67,
as described earlier, and counted based on PKH67 positive events
falling under 1 mm in size.
Recipient mice were separated into two groups, healthy and
PbA infected. PbA infected mice were infected 5 days prior to the
EMP purifications to allow MP and mice to be ready at the same
time. These groups were further divided to account for the
experimental conditions (n=3 per group). On day 4 p.i, mice were
intravenously injected with PBS, inert microspheres (4006103
beads/mouse), NS-EMP (4006103 MP/mouse) or TNF-EMP
(4006103 MP/mouse). All mice were monitored, and the kinetics
of clearance was measured for 60 min using flow cytometry, as
described earlier. All mice were sacrificed on day 7 and brain and
lung tissue were harvested for histological analysis.
ii. Histology. Formalin fixed, paraffin embedded brain and
lung were Haematoxylin-Eosin stained. Slides were imaged at
1006magnification using an Olympus IX71 inverted microscope.
Qualitative assessment of the tissue was performed by two
independent researchers using parameters stipulated in the
histopathological scale (Table 3). The brain was assessed for signs
of oedema, haemorrhages and sequestered cells in vessels, and the
lung was scored for cellularity in the alveolar septa, atelectasis, and
intra-alveolar plasma and haemorrhages.
Statistical analysis
Data were analysed using GraphPad Prism version 5.00 for
Windows, GraphPad Software, San Diego California USA.
Survival curves were analysed using the Log-rank (Mantel-Cox)
Test and the Gehan-Breslow-Wilcoxon Test. To compare several
groups, we used non-parametric analysis of variance (ANOVA,
Kruskall-Wallis) with a Dunn’s post-test. To compare mean total
and cell-specific MP levels between two groups the Wilcoxon test
was used; *p,0.05, **p,0.001, ***p,0.0001.
Supporting Information
Figure S1 High levels of PKH67-labelled MP (green)
localised in the spleen following adoptive transfer, with
less to none distributed in the brain, lung, liver, kidney
and heart. Cryosections were prepared from recipient mice with
CD105-PE-labelled vessels (red) and DAPI-labelled nuclei (blue).
Arrows indicate trapped MP, magnification (6400). Spleen (S),
lung (L), kidney (K), liver (Li), brain (B) and heart (H).
(PDF)
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